Expand SLXN Menu
SLXN MENU

SLXN Latest Press Releases

-- December 16, 2025 --

Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer Globe Newswire 8:40 AM

-- December 2, 2025 --

Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer Globe Newswire 8:00 AM

-- November 26, 2025 --

Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference Globe Newswire 7:30 AM

-- November 25, 2025 --

Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer Globe Newswire 9:15 AM

-- November 12, 2025 --

Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update Globe Newswire 9:00 AM

-- September 30, 2025 --

Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer Globe Newswire 8:40 AM

-- September 25, 2025 --

Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements Globe Newswire 8:45 AM

-- September 11, 2025 --

Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering Globe Newswire 9:16 AM
Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204's Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration Globe Newswire 7:00 AM

-- September 4, 2025 --

Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204 Globe Newswire 9:25 AM

-- September 2, 2025 --

Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference Globe Newswire 8:45 AM

-- August 12, 2025 --

Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Globe Newswire 8:00 AM

-- July 31, 2025 --

Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds Globe Newswire 8:00 PM
Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation Globe Newswire 9:55 AM

-- July 16, 2025 --

Silexion Therapeutics Announces 1-for-15 Reverse Share Split Globe Newswire 8:44 AM
Market Data Delayed 15 Minutes